Drug Profile
Anti-CD19 chimeric antigen receptor T-cell therapies - Wuhan Bio Raid Biotechnology
Alternative Names: anti-CD19 CAR-T therapyLatest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Wuhan Bio-Raid Biotechnology
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Haematological malignancies
- No development reported B-cell lymphoma
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for clinical-Phase-Unknown development in B-cell lymphoma(Refractory metastatic disease, Second-line therapy or greater) in China (Parenteral, Infusion)
- 11 Jun 2020 Pooled efficacy and adverse event data from the two pilot clinical trial in B-cell lymphoma and Haematological malignancies presented at the 25th Congress of the European Haematology Association (EHA-2020)
- 01 Dec 2018 Efficacy and adverse events data from a clinical trial in B-cell lymphoma presented at the 60th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem 2018 (3367649)